AcelRx

AcelRx pain drug shows mixed results in mid-stage trial

AcelRx pain drug shows mixed results in mid-stage trial

Reuters

This Week in Biotech

This Week in Biotech

Motley Fool

4 Healthcare Stock Stories for Tuesday Investment Wellness

4 Healthcare Stock Stories for Tuesday Investment Wellness

Wall Street Cheat Street

AcelRx post-operative pain treatment meets late-stage study goal

AcelRx post-operative pain treatment meets late-stage study goal

Reuters

AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts

AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts

Seeking Alpha

Favorable AcelRx Stock Offering Price May Catalyze The Company's Share Price

Favorable AcelRx Stock Offering Price May Catalyze The Company's Share Price

Seeking Alpha

AcelRx phase III study of sublingual Sufentanil NanoTab PCA vs IV PCA morphine for post operative pain meets primary endpoint

AcelRx phase III study of sublingual Sufentanil NanoTab PCA vs IV PCA morphine for post operative pain meets primary endpoint

Pharmabiz

2 Biotech Companies Investors Should Watch As Analysts Initiate Buy Ratings

2 Biotech Companies Investors Should Watch As Analysts Initiate Buy Ratings

Seeking Alpha

5 Pharmaceutical Companies To Present At The Rodman And Renshaw Conference On September 11

5 Pharmaceutical Companies To Present At The Rodman And Renshaw Conference On September 11

Seeking Alpha

4 Reasons To Buy AcelRx Pharmaceuticals

4 Reasons To Buy AcelRx Pharmaceuticals

Seeking Alpha

AcelRx